Revenue from operations grew nearly 12% to Rs 1,224.36 crore in Q3 FY22 from Rs 1,095 crore registered in Q3 FY21. Profit before tax rose 12% to Rs 266.65 crore in Q3 FY22 over Q3 FY21.
Total expenses surged 12% to Rs 976.45 crore in Q3 FY22 as compared to Rs 872.50 crore posted in the corresponding period last year.
Meanwhile, the drug maker announced the appointment of Vivek V Kamath as an additional director and MD for a term of five years with effect from 15 February 2022, subject to the approval by the shareholders.
Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
